Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.

Kaseb A, Vence L, Blando J, Yadav S, Ikoma N, Pestana R, Vauthey J, Cao H, Chun Y, Sakamura D, Wolff R, Yao J, Allison J, Sharma P.

Ann Oncol. 2019 Jul;30 Suppl 4:iv112. doi: 10.1093/annonc/mdz156.008. Epub 2019 Dec 4. No abstract available.

PMID:
32084976
2.

Hospital Security Programs and Policies Related to Guns and Other Weapons.

Blando JD, Cramer RJ, Szklo-Coxe M.

J Healthc Manag. 2019 May-Jun;64(3):157-166. doi: 10.1097/JHM-D-18-00046.

PMID:
31999265
3.

B cells and tertiary lymphoid structures promote immunotherapy response.

Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Sautès-Fridman C, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, Wang L, Wargo JA.

Nature. 2020 Jan;577(7791):549-555. doi: 10.1038/s41586-019-1922-8. Epub 2020 Jan 15.

PMID:
31942075
4.

Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma.

Goswami S, Walle T, Cornish AE, Basu S, Anandhan S, Fernandez I, Vence L, Blando J, Zhao H, Yadav SS, Ott M, Kong LY, Heimberger AB, de Groot J, Sepesi B, Overman M, Kopetz S, Allison JP, Pe'er D, Sharma P.

Nat Med. 2020 Jan;26(1):39-46. doi: 10.1038/s41591-019-0694-x. Epub 2019 Dec 23.

PMID:
31873309
5.

High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer.

Massarelli E, Lam VK, Parra ER, Rodriguez-Canales J, Behrens C, Diao L, Wang J, Blando J, Byers LA, Yanamandra N, Brett S, Morley P, Sharma P, Allison J, Wistuba II, Heymach JV.

J Immunother Cancer. 2019 Dec 16;7(1):351. doi: 10.1186/s40425-019-0827-2.

6.

Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.

de Groot J, Penas-Prado M, Alfaro-Munoz KD, Hunter K, Pei B, O'brien B, Weathers SP, Loghin M, Kamiya Matsouka C, Yung WKA, Mandel J, Wu J, Yuan Y, Zhou S, Fuller GN, Huse J, Rao G, Weinberg JS, Prabhu SS, McCutcheon IE, Lang FF, Ferguson SD, Sawaya R, Colen R, Yadav SS, Blando J, Vence L, Allison J, Sharma P, Heimberger AB.

Neuro Oncol. 2019 Nov 22. pii: noz185. doi: 10.1093/neuonc/noz185. [Epub ahead of print]

PMID:
31755915
7.

Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities.

Tahir SA, Gao J, Miura Y, Blando J, Tidwell RSS, Zhao H, Subudhi SK, Tawbi H, Keung E, Wargo J, Allison JP, Sharma P.

Proc Natl Acad Sci U S A. 2019 Oct 29;116(44):22246-22251. doi: 10.1073/pnas.1908079116. Epub 2019 Oct 14.

PMID:
31611368
8.

Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner.

Shi LZ, Goswami S, Fu T, Guan B, Chen J, Xiong L, Zhang J, Ng Tang D, Zhang X, Vence L, Blando J, Allison JP, Collazo R, Gao J, Sharma P.

Cancer Immunol Res. 2019 Nov;7(11):1803-1812. doi: 10.1158/2326-6066.CIR-18-0873. Epub 2019 Aug 29.

PMID:
31466995
9.

Characterization and Comparison of GITR Expression in Solid Tumors.

Vence L, Bucktrout SL, Fernandez Curbelo I, Blando J, Smith BM, Mahne AE, Lin JC, Park T, Pascua E, Sai T, Chaparro-Riggers J, Subudhi SK, Scutti JB, Higa MG, Zhao H, Yadav SS, Maitra A, Wistuba II, Allison JP, Sharma P.

Clin Cancer Res. 2019 Nov 1;25(21):6501-6510. doi: 10.1158/1078-0432.CCR-19-0289. Epub 2019 Jul 29.

PMID:
31358539
10.

Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma.

Kaseb AO, Vence L, Blando J, Yadav SS, Ikoma N, Pestana RC, Vauthey JN, Allison JP, Sharma P.

Cancer Immunol Res. 2019 Sep;7(9):1390-1395. doi: 10.1158/2326-6066.CIR-18-0605. Epub 2019 Jul 9.

PMID:
31289040
11.

Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Response.

Sharma A, Subudhi SK, Blando J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P.

Clin Cancer Res. 2019 Jun 1;25(11):3469-3470. doi: 10.1158/1078-0432.CCR-19-0402. No abstract available.

12.

Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer.

Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, Wargo J, Tetzlaff M, Broaddus R, Katz MHG, Varadhachary GR, Overman M, Wang H, Yee C, Bernatchez C, Iacobuzio-Donahue C, Basu S, Allison JP, Sharma P.

Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1692-1697. doi: 10.1073/pnas.1811067116. Epub 2019 Jan 11.

13.

Levels of CD8+ tumor infiltrating lymphocytes correlate with disease burden in bone marrow of therapy Naïve multiple myeloma patients.

Hidalgo-Lopez JE, Higa MG, Ferrian S, Lin P, Blando J, Medeiros LJ, Bueso-Ramos CE.

Ann Diagn Pathol. 2019 Jun;40:174-175. doi: 10.1016/j.anndiagpath.2018.11.008. Epub 2018 Nov 28. No abstract available.

PMID:
30509755
14.

The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.

Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG.

Cancer. 2019 May 1;125(9):1470-1481. doi: 10.1002/cncr.31896. Epub 2018 Nov 30.

15.

Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.

Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR.

Nat Med. 2019 Jan;25(1):188. doi: 10.1038/s41591-018-0305-2.

PMID:
30479380
16.

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.

Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR.

Nat Med. 2018 Dec;24(12):1804-1808. doi: 10.1038/s41591-018-0238-9. Epub 2018 Nov 12. Erratum in: Nat Med. 2018 Nov 27;:.

17.

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.

Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H.

Cancer Discov. 2019 Mar;9(3):370-383. doi: 10.1158/2159-8290.CD-18-0774. Epub 2018 Nov 8.

18.

Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Dec;24(12):1942. doi: 10.1038/s41591-018-0252-y.

PMID:
30361511
19.

Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0251-z.

PMID:
30361510
20.

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Nov;24(11):1649-1654. doi: 10.1038/s41591-018-0197-1. Epub 2018 Oct 8. Erratum in: Nat Med. 2018 Oct 25;:. Nat Med. 2018 Oct 25;:.

21.

Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers.

Sharma A, Subudhi SK, Blando J, Scutti J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P.

Clin Cancer Res. 2019 Feb 15;25(4):1233-1238. doi: 10.1158/1078-0432.CCR-18-0762. Epub 2018 Jul 27.

22.

COX-2 mediates pro-tumorigenic effects of PKCε in prostate cancer.

Garg R, Blando JM, Perez CJ, Lal P, Feldman MD, Smyth EM, Ricciotti E, Grosser T, Benavides F, Kazanietz MG.

Oncogene. 2018 Aug;37(34):4735-4749. doi: 10.1038/s41388-018-0318-9. Epub 2018 May 16.

23.

Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade.

Ariyan CE, Brady MS, Siegelbaum RH, Hu J, Bello DM, Rand J, Fisher C, Lefkowitz RA, Panageas KS, Pulitzer M, Vignali M, Emerson R, Tipton C, Robins H, Merghoub T, Yuan J, Jungbluth A, Blando J, Sharma P, Rudensky AY, Wolchok JD, Allison JP.

Cancer Immunol Res. 2018 Feb;6(2):189-200. doi: 10.1158/2326-6066.CIR-17-0356. Epub 2018 Jan 16.

24.

Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy.

Nejati R, Goldstein JB, Halperin DM, Wang H, Hejazi N, Rashid A, Katz MH, Lee JE, Fleming JB, Rodriguez-Canales J, Blando J, Wistuba II, Maitra A, Wolff RA, Varadhachary GR, Wang H.

Pancreas. 2017 Oct;46(9):1180-1187. doi: 10.1097/MPA.0000000000000914.

25.

Proinflammatory CXCL12-CXCR4/CXCR7 Signaling Axis Drives Myc-Induced Prostate Cancer in Obese Mice.

Saha A, Ahn S, Blando J, Su F, Kolonin MG, DiGiovanni J.

Cancer Res. 2017 Sep 15;77(18):5158-5168. doi: 10.1158/0008-5472.CAN-17-0284. Epub 2017 Jul 7.

26.

Workplace Violence and Training Required by New Legislation Among NJ Nurses.

Ridenour ML, Hendricks S, Hartley D, Blando JD.

J Occup Environ Med. 2017 Apr;59(4):e35-e40. doi: 10.1097/JOM.0000000000000973.

PMID:
28628055
27.

Protein Kinase C Epsilon Cooperates with PTEN Loss for Prostate Tumorigenesis through the CXCL13-CXCR5 Pathway.

Garg R, Blando JM, Perez CJ, Abba MC, Benavides F, Kazanietz MG.

Cell Rep. 2017 Apr 11;19(2):375-388. doi: 10.1016/j.celrep.2017.03.042.

28.

VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.

Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P.

Nat Med. 2017 May;23(5):551-555. doi: 10.1038/nm.4308. Epub 2017 Mar 27.

29.

Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study.

Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, Xiao L, Bekaii-Saab T, Vence L, Blando J, Mahvash A, Foo WC, Ohaji C, Pasia M, Bland G, Ohinata A, Rogers J, Mehdizadeh A, Banks K, Lanman R, Wolff RA, Streicher H, Allison J, Sharma P, Eng C.

Lancet Oncol. 2017 Apr;18(4):446-453. doi: 10.1016/S1470-2045(17)30104-3. Epub 2017 Feb 18.

30.

Workplace violence and hospital security programs: regulatory compliance, program benchmarks, innovative strategies.

Blando JD, Nocera M, Ridenour ML, Hartley D.

J Healthc Prot Manage. 2017;33(1):89-105.

PMID:
30351554
31.

Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy.

Shi LZ, Fu T, Guan B, Chen J, Blando JM, Allison JP, Xiong L, Subudhi SK, Gao J, Sharma P.

Nat Commun. 2016 Aug 8;7:12335. doi: 10.1038/ncomms12335.

32.

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.

Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA.

Cancer Discov. 2016 Aug;6(8):827-37. doi: 10.1158/2159-8290.CD-15-1545. Epub 2016 Jun 14.

33.

Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients.

Parra ER, Behrens C, Rodriguez-Canales J, Lin H, Mino B, Blando J, Zhang J, Gibbons DL, Heymach JV, Sepesi B, Swisher SG, Weissferdt A, Kalhor N, Izzo J, Kadara H, Moran C, Lee JJ, Wistuba II.

Clin Cancer Res. 2016 Dec 15;22(24):6278-6289. Epub 2016 Jun 1.

34.
35.

Barriers to Effective Implementation of Programs for the Prevention of Workplace Violence in Hospitals.

Blando J, Ridenour M, Hartley D, Casteel C.

Online J Issues Nurs. 2015 Jan;20(1). pii: 5. Epub 2014 Dec 4.

36.

Household bush burning practice and related respiratory symptoms in Grenada, the Caribbean.

Akpinar-Elci M, Coomansingh K, Blando J, Mark L.

J Air Waste Manag Assoc. 2015 Sep;65(9):1148-52. doi: 10.1080/10962247.2015.1070773.

PMID:
26199071
37.

Effect of Metformin, Rapamycin, and Their Combination on Growth and Progression of Prostate Tumors in HiMyc Mice.

Saha A, Blando J, Tremmel L, DiGiovanni J.

Cancer Prev Res (Phila). 2015 Jul;8(7):597-606. doi: 10.1158/1940-6207.CAPR-15-0014. Epub 2015 Apr 23.

38.
39.

6-Shogaol from dried ginger inhibits growth of prostate cancer cells both in vitro and in vivo through inhibition of STAT3 and NF-κB signaling.

Saha A, Blando J, Silver E, Beltran L, Sessler J, DiGiovanni J.

Cancer Prev Res (Phila). 2014 Jun;7(6):627-38. doi: 10.1158/1940-6207.CAPR-13-0420. Epub 2014 Apr 1.

40.

Barriers to Effective Implementation of Programs for the Prevention of Workplace Violence in Hospitals.

Blando J, Ridenour M, Hartley D, Casteel C.

Online J Issues Nurs. 2014 Dec 4;20(1):7.

41.

Metformin inhibits skin tumor promotion in overweight and obese mice.

Checkley LA, Rho O, Angel JM, Cho J, Blando J, Beltran L, Hursting SD, DiGiovanni J.

Cancer Prev Res (Phila). 2014 Jan;7(1):54-64. doi: 10.1158/1940-6207.CAPR-13-0110. Epub 2013 Nov 6.

42.

Variability and trend of multiple blood lead measures among construction and manufacturing workers.

Blando J, Lu SE, Gu H, Lin Y, Marshall EG.

Occup Environ Med. 2013 Nov;70(11):774-81. doi: 10.1136/oemed-2013-101370. Epub 2013 Jul 9.

PMID:
23839661
43.

Lead-based paint awareness, work practices, and compliance during residential construction and renovation.

Blando JD, Antoine N, Lefkowitz D.

J Environ Health. 2013 May;75(9):20-7; quiz 51.

PMID:
23734528
44.

Antitumor activity of tumor-targeted RNA replicase-based plasmid that expresses interleukin-2 in a murine melanoma model.

Rodriguez BL, Blando JM, Lansakara-P DS, Kiguchi Y, DiGiovanni J, Cui Z.

Mol Pharm. 2013 Jun 3;10(6):2404-15. doi: 10.1021/mp400033m. Epub 2013 May 17.

45.

Impact of hospital security programmes and workplace aggression on nurse perceptions of safety.

Blando JD, O'Hagan E, Casteel C, Nocera MA, Peek-Asa C.

J Nurs Manag. 2013 Apr;21(3):491-8. doi: 10.1111/j.1365-2834.2012.01416.x. Epub 2012 Jul 10.

PMID:
23406321
46.

Stearoyl gemcitabine nanoparticles overcome obesity-induced cancer cell resistance to gemcitabine in a mouse postmenopausal breast cancer model.

De Angel RE, Blando JM, Hogan MG, Sandoval MA, Lansakara-P DS, Dunlap SM, Hursting SD, Cui Z.

Cancer Biol Ther. 2013 Apr;14(4):357-64. doi: 10.4161/cbt.23623. Epub 2013 Jan 28.

47.

Activation of nuclear factor κB (NF-κB) in prostate cancer is mediated by protein kinase C epsilon (PKCepsilon).

Garg R, Blando J, Perez CJ, Wang H, Benavides FJ, Kazanietz MG.

J Biol Chem. 2012 Oct 26;287(44):37570-82. doi: 10.1074/jbc.M112.398925. Epub 2012 Sep 6.

48.

Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer.

Yang G, Goltsov AA, Ren C, Kurosaka S, Edamura K, Logothetis R, DeMayo FJ, Troncoso P, Blando J, DiGiovanni J, Thompson TC.

Mol Cancer Res. 2012 Feb;10(2):218-29. doi: 10.1158/1541-7786.MCR-11-0451. Epub 2011 Dec 5.

49.

Dietary energy balance modulates prostate cancer progression in Hi-Myc mice.

Blando J, Moore T, Hursting S, Jiang G, Saha A, Beltran L, Shen J, Repass J, Strom S, DiGiovanni J.

Cancer Prev Res (Phila). 2011 Dec;4(12):2002-14. doi: 10.1158/1940-6207.CAPR-11-0182. Epub 2011 Sep 27.

50.

Protective role of cathepsin L in mouse skin carcinogenesis.

Benavides F, Perez C, Blando J, Contreras O, Shen J, Coussens LM, Fischer SM, Kusewitt DF, DiGiovanni J, Conti CJ.

Mol Carcinog. 2012 Apr;51(4):352-61. doi: 10.1002/mc.20792. Epub 2011 May 2.

Supplemental Content

Loading ...
Support Center